Seer, Inc. SEER

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
51/100
Moderate

Ranked against 712 peers in Biotechnology

About Seer, Inc.

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets … Full SEER analysis →

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.71), demonstrating pricing resilience across cycles.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.86), providing operational cushion.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.24), suggesting weak customer stickiness.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.39), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
40
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where SEER ranks in Biotechnology

Seer, Inc. ranks #230 of 713 scored companies in Biotechnology by moat score — the top 32%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
226 Quince Therapeutics, Inc. QNCX 51/100 Moderate
227 Brainstorm Cell Therapeutics In BCLI 51/100 Moderate
228 Scholar Rock Holding Corporatio SRRK 51/100 Moderate
229 Rhythm Pharmaceuticals, Inc. RYTM 51/100 Moderate
230 Seer, Inc. SEER 51/100 Moderate
231 Xilio Therapeutics, Inc. XLO 51/100 Moderate
232 4D Molecular Therapeutics, Inc. FDMT 51/100 Moderate
233 Acrivon Therapeutics, Inc. ACRV 51/100 Moderate
234 Enliven Therapeutics, Inc. ELVN 51/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How SEER scores on the Corporate Default defenses

Pricing Power

Score 40 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 49 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 44 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 55 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 75 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 52 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SEER's moat

What is Seer, Inc.'s moat score?

Seer, Inc. (SEER) scores 51 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #230 of 713 scored companies in Biotechnology, the top 32%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (75/100) and its weakest is Pricing Power (40/100).

How does Seer, Inc. compare with other Biotechnology companies?

Seer, Inc. ranks #230 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Rhythm Pharmaceuticals, Inc. (RYTM) at 51 just above it and Xilio Therapeutics, Inc. (XLO) at 51 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Seer, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Seer, Inc.?

The Corporate Default template measures 6 defenses, and SEER scores: Pricing Power (40), Cost Advantage (49), Customer Stickiness (44), Capital Efficiency (55), Resilience (75), Scale & Market Position (52). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000